Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Other Accumulated Expenses (2017 - 2025)

Sutro Biopharma's Other Accumulated Expenses history spans 9 years, with the latest figure at $15.8 million for Q3 2025.

  • For Q3 2025, Other Accumulated Expenses rose 356.33% year-over-year to $15.8 million; the TTM value through Sep 2025 reached $15.8 million, up 356.33%, while the annual FY2024 figure was $4.0 million, 3.34% up from the prior year.
  • Other Accumulated Expenses for Q3 2025 was $15.8 million at Sutro Biopharma, down from $17.8 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $17.8 million in Q2 2025 and bottomed at $185000.0 in Q1 2021.
  • The 5-year median for Other Accumulated Expenses is $3.5 million (2024), against an average of $5.1 million.
  • The largest annual shift saw Other Accumulated Expenses plummeted 91.39% in 2021 before it soared 1408.11% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $2.8 million in 2021, then rose by 12.0% to $3.1 million in 2022, then rose by 26.53% to $3.9 million in 2023, then increased by 3.34% to $4.0 million in 2024, then skyrocketed by 292.08% to $15.8 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Other Accumulated Expenses are $15.8 million (Q3 2025), $17.8 million (Q2 2025), and $14.2 million (Q1 2025).